Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Status:
Completed
Trial end date:
2016-10-20
Target enrollment:
Participant gender:
Summary
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g
idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or
require emergency surgery or procedures.